Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eli Lilly & Co ( (LLY) ) has provided an update.
On May 20, 2026, Eli Lilly and Company completed a multibillion-dollar debt offering, issuing a mix of floating-rate and fixed-rate notes maturing between 2028 and 2066, for net proceeds of about $8.94 billion after underwriting discounts. The offering, arranged with major underwriters including Morgan Stanley, Citigroup, Deutsche Bank and Goldman Sachs, features floating-rate tranches linked to Compounded SOFR and fixed-rate tranches with coupons ranging from 4.375% to 5.700%.
The structure of the notes gives Eli Lilly flexibility in managing its capital while embedding provisions tied to its planned acquisition of Centessa, including a special mandatory redemption of several series at 101% of principal plus accrued interest if that deal is not completed by an agreed outside date or is abandoned. Certain longer-dated notes are excluded from this Centessa-linked redemption, underscoring that a substantial portion of the issuance is designed both to fund the acquisition and to support broader long-term financing needs, with implications for bondholders’ call and redemption risk profiles.
The most recent analyst rating on (LLY) stock is a Buy with a $1500.00 price target. To see the full list of analyst forecasts on Eli Lilly & Co stock, see the LLY Stock Forecast page.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
The score is driven primarily by outstanding financial performance and a strongly positive earnings call with raised guidance. Offsetting factors are a premium valuation and mixed/neutral technical signals, with leverage and pricing pressure remaining key risks to monitor.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
Eli Lilly and Company is a global pharmaceutical manufacturer focused on developing, producing and marketing prescription medicines. The company operates in the healthcare sector, with a portfolio that spans therapies for chronic and acute conditions, and it frequently taps debt markets to support strategic transactions and long-term growth initiatives.
Average Trading Volume: 3,093,925
Technical Sentiment Signal: Strong Buy
Current Market Cap: $930.5B
For detailed information about LLY stock, go to TipRanks’ Stock Analysis page.